Heidi Christensen, MD
Sports Medicine · Castle Pines, CONPI 1013146729
Payments from drug & device makers
Across 136 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$528
- Novo Nordisk$493
- AbbVie$491
- GSK$212
- Idorsia Pharmaceuticals US Inc$181
- Lilly USA, LLC$149
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,180100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $528 |
| Novo Nordisk | 22 | $493 |
| AbbVie(2 entities) | 18 | $491 |
| GSK | 6 | $212 |
| Idorsia Pharmaceuticals US Inc | 5 | $181 |
| Lilly USA, LLC | 9 | $149 |
| Amgen | 7 | $136 |
| Boston Scientific | 3 | $86 |
| Exact Sciences | 4 | $67 |
| Hologic Sales And Service, LLC | 3 | $63 |
| Pfizer | 4 | $62 |
| Johnson & Johnson | 2 | $60 |
| Myriad Women's Health, Inc. | 1 | $50 |
| Novartis | 2 | $46 |
| Bioventus LLC | 2 | $45 |
| Smith+Nephew | 1 | $43 |
| Merck | 2 | $32 |
| Abiomed | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Exeltis, USA Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Merz North America, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Si-bone, Inc. | 1 | $18 |
| Avita Medical Americas, LLC | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Sonex Health, Inc. | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Vertex | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$122
- Saxenda$122
- TRELEGY ELLIPTA$121
- AIRSUPRA$121
- UBRELVY$113
How this compares
$3,180 in reported general payments places this provider in the 40th percentile of 196 sports medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 21 | $74 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Castle Pines
- Peter MillettVail$22.2M
- Matthew ProvencherVail$4.2M
- Rachel FrankAurora$1.8M
- Alan NgDenver$1.6M
- David WeinsteinColorado Springs$1.5M
- Christopher JonesColorado Springs$1.2M
- James GenuarioParker$751K
- David SchneiderGolden$746K
- Randall ViolaVail$551K
- Jonathan BravmanAurora$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.